INSM Insmed Incorporated

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • FDA accelerated approval of ARIKAYCE contingent on successful ENCORE confirmatory trial with 425 patients enrolled as of Q4 2024
• • Exposure to inflation affecting suppliers, service providers, and partners across US, Europe, Japan, and global operations
• • Dependence on Lamira device regulatory approval in each market for ARIKAYCE commercialization limits product sales capability
• • Competitive market risks amid reliance on market acceptance against alternatives amid safety concerns like US boxed warning on ARIKAYCE
• • Outstanding term loan and royalty financing arrangement may limit financial flexibility and increase risk of shareholder dilution

Management Discussion & Analysis

• • Revenue not disclosed in provided text, no YoY change available
• • Profitability or margin details not provided in the excerpt
• • Respiratory therapeutic area is the only commercial segment with two approved products: ARIKAYCE and BRINSUPRI
• • No cash flow, buybacks, dividends, or capex details mentioned
• • Forward-looking: portfolio focused on Respiratory, Inflammation & Immunology, Neuro & Rare diseases, with ongoing clinical and pre-clinical programs spanning advanced modalities

Business Overview

• • Core business model: Development and commercialization of specialty pharmaceuticals focusing on respiratory diseases, including key marketed products ARIKAYCE and BRINSUPRI
• • New product emphasis: BRINSUPRI launch in August 2025 generated $172.7M US sales in 2025, contributing to 66.7% overall revenue growth to $606.4M
• • Strategic shift: Accelerated commercial readiness and significant investment in BRINSUPRI’s US launch, plus acquisition of INS1148 for $40M in 2025, expanding pipeline
• • Notable quantitative metrics: R&D expenses rose 28.9% to $771.1M, SG&A increased 52.1% to $701.2M, driven by headcount growth and commercial activities for BRINSUPRI
• • Unique fact: Completed two large equity offerings in 2024 and 2025, raising net proceeds of $713.2M and $823.3M respectively, bolstering cash reserves to support operations

What are the latest INSM SEC filings in 2026?

Insmed Incorporated (INSM) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on July 16, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did INSM file its most recent 10-K annual report?

Insmed Incorporated (INSM) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view INSM 10-Q quarterly reports?

Insmed Incorporated (INSM)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every INSM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has INSM filed recently?

Insmed Incorporated (INSM)'s most recent 8-K was filed on July 16, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find INSM insider trading activity (Form 4)?

SignalX aggregates every INSM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does INSM file with the SEC?

Insmed Incorporated (INSM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new INSM filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Insmed Incorporated (INSM).

What is INSM's SEC CIK number?

Insmed Incorporated (INSM)'s SEC CIK (Central Index Key) number is 1104506. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1104506 to look up all INSM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find INSM return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Insmed Incorporated (INSM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.